|
1
|
Haggar FA and Boushey RP: Colorectal
cancer epidemiology: Incidence, mortality, survival, and risk
factors. Clin Colon Rectal Surg. 22:191–197. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Weng W, Wei Q, Toden S, Yoshida K,
Nagasaka T, Fujiwara T, Cai S, Qin H, Ma Y and Goel A: Circular RNA
ciRS-7-a promising prognostic biomarker and a potential therapeutic
target in colorectal cancer. Clin Cancer Res. 23:3918–3928. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Zeng J, Tang ZH, Liu S and Guo SS:
Clinicopathological significance of overexpression of interleukin-6
in colorectal cancer. World J Gastroenterol. 23:1780–1786. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Deng J, Lei W, Fu JC, Zhang L, Li JH and
Xiong JP: Targeting miR-21 enhances the sensitivity of human colon
cancer HT-29 cells to chemoradiotherapy in vitro. Biochem Biophys
Res Commun. 443:789–795. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Wieser M, Sauerland S, Arnold D, Schmiegel
W and Reinacher-Schick A: Peri-operative chemotherapy for the
treatment of resectable liver metastases from colorectal cancer: A
systematic review and meta-analysis of randomized trials. BMC
Cancer. 10:309–321. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Moghimi-Dehkordi B and Safaee A: An
overview of colorectal cancer survival rates and prognosis in Asia.
World J Gastrointest Oncol. 4:71–75. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Karin M and Greten FR: NF-kappaB: Linking
inflammation and immunity to cancer development and progression.
Nat Rev Immunol. 5:749–759. 2005. View
Article : Google Scholar : PubMed/NCBI
|
|
8
|
Hayden MS and Ghosh S: Shared principles
in NF-kappaB signaling. Cell. 132:344–362. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Hoesel B and Schmid JA: The complexity of
NF-κB signaling in inflammation and cancer. Mol Cancer. 12:862013.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Wu D, Wu P, Zhao L, Huang L, Zhang Z, Zhao
S and Huang J: NF-κB expression and outcomes in solid tumors: A
systematic review and meta-analysis. Medicine (Baltimore).
94:e16872015. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Chen Z, Zhao L, Zhao F, Yang G and Wang J:
MicroRNA-26b regulates cancer proliferation migration and cell
cycle transition by suppressing TRAF5 in esophageal squamous cell
carcinoma. Am J Transl Res. 8:1957–1970. 2016.PubMed/NCBI
|
|
12
|
Jiang L, Yu L, Zhang X, Lei F, Wang L, Liu
X, Wu S, Zhu J, Wu G, Cao L, et al: miR-892b silencing activates
NF-κB and promotes aggressiveness in breast cancer. Cancer Res.
76:1101–1111. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Harhaj EW and Dixit VM: Deubiquitinases in
the regulation of NF-κB signaling. Cell Res. 21:22–39. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Khella HWZ, Daniel N, Youssef L, Scorilas
A, Nofech-Mozes R, Mirham L, Krylov SN, Liandeau E, Krizova A,
Finelli A, et al: miR-10b is a prognostic marker in clear cell
renal cell carcinoma. J Clin Pathol. 70:854–859. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Chen J, Wang M, Guo M, Xie Y and Cong YS:
miR-127 regulates cell proliferation and senescence by targeting
BCL6. PLoS One. 8:e802662013. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Li M, Wang Y, Song Y, Bu R, Yin B, Fei X,
Guo Q and Wu B: MicroRNAs in renal cell carcinoma: A systematic
review of clinical implications (Review). Oncol Rep. 33:1571–1578.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Zhao G, Cai C, Yang T, Qiu X, Liao B, Li
W, Ji Z, Zhao J, Zhao H, Guo M, et al: MicroRNA-221 induces cell
survival and cisplatin resistance through PI3K/Akt pathway in human
osteosarcoma. PLoS One. 8:e539062013. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Go H, Jang JY, Kim PJ, Kim YG, Nam SJ,
Paik JH, Kim TM, Heo DS, Kim CW and Jeon YK: MicroRNA-21 plays an
oncogenic role by targeting FOXO1 and activating the PI3K/AKT
pathway in diffuse large B-cell lymphoma. Oncotarget.
6:15035–15049. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Li Y, VandenBoom TG II, Kong D, Wang Z,
Ali S, Philip PA and Sarkar FH: Up-regulation of miR-200 and let-7
by natural agents leads to the reversal of
epithelial-to-mesenchymal transition in gemcitabine-resistant
pancreatic cancer cells. Cancer Res. 69:6704–6712. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Peng Y, Liu YM, Li LC, Wang LL and Wu XL:
microRNA-503 inhibits gastric cancer cell growth and
epithelial-to-mesenchymal transition. Oncol Lett. 7:1233–1238.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Nofech-Mozes R, Khella HW, Scorilas A,
Youssef L, Krylov SN, Lianidou E, Sidiropoulos KG, Gabril M, Evans
A and Yousef GM: MicroRNA-194 is a marker for good prognosis in
clear cell renal cell carcinoma. Cancer Med. 5:656–664. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Rapti SM, Kontos CK, Papadopoulos IN and
Scorilas A: High miR-96 levels in colorectal adenocarcinoma predict
poor prognosis, particularly in patients without distant metastasis
at the time of initial diagnosis. Tumour Biol. 37:11815–11824.
2016. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Lee TS, Jeon HW, Kim YB, Kim YA, Kim MA
and Kang SB: Aberrant microRNA expression in endometrial carcinoma
using formalin-fixed paraffin-embedded (FFPE) tissues. PLoS One.
8:e814212013. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Skalsky RL and Cullen BR: Reduced
expression of brain-enriched microRNAs in glioblastomas permits
targeted regulation of a cell death gene. PLoS One. 6:e242482011.
View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Wang RJ, Li JW, Bao BH, Wu HC, Du ZH, Su
JL, Zhang MH and Liang HQ: MicroRNA-873 (miRNA-873) inhibits
glioblastoma tumorigenesis and metastasis by suppressing the
expression of IGF2BP1. J Biol Chem. 290:8938–8948. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Chen X, Zhang Y, Shi Y, Lian H, Tu H, Han
S, Peng B, Liu W and He X: miR-873 acts as a novel sensitizer of
glioma cells to cisplatin by targeting Bcl-2. Int J Oncol.
47:1603–1611. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Wu DD, Li XS, Meng XN, Yan J and Zong ZH:
MicroRNA-873 mediates multidrug resistance in ovarian cancer cells
by targeting ABCB1. Tumour Biol. 37:10499–10506. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Cui J, Bi M, Overstreet AM, Yang Y, Li H,
Leng Y, Qian K, Huang Q, Zhang C, Lu Z, et al: miR-873 regulates
Erα transcriptional activity and tamoxifen resistance via targeting
CDK3 in breast cancer cells. Oncogene. 22:1–13. 2014.
|
|
29
|
Gao Y, Xue Q, Wang D, Du M, Zhang Y and
Gao S: miR-873 induces lung adenocarcinoma cell proliferation and
migration by targeting SRCIN1. Am J Transl Res. 7:2519–2526.
2015.PubMed/NCBI
|
|
30
|
Liao WT, Ye YP, Zhang NJ, Li TT, Wang SY,
Cui YM, Qi L, Wu P, Jiao HL, Xie YJ, et al: MicroRNA-30b functions
as a tumour suppressor in human colorectal cancer by targeting
KRAS, PIK3CD and BCL2. J Pathol. 232:415–427. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Miao Y, Li J, Qiu X, Li Y, Wang Z and Luan
Y: miR-27a regulates the self renewal of the H446 small cell lung
cancer cell line in vitro. Oncol Rep. 29:161–168. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Li XX, Huang LY, Peng JJ, Liang L, Shi DB,
Zheng HT and Cai SJ: Klotho suppresses growth and invasion of colon
cancer cells through inhibition of IGF1R-mediated PI3K/AKT pathway.
Int J Oncol. 45:611–618. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Qu L, Deng B, Zeng Y and Cao Z: Decreased
expression of the Nkx2.8 gene correlates with tumor progression and
a poor prognosis in HCC cancer. Cancer Cell Int. 14:282014.
View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Michael MZ, O' Connor SM, van Holst
Pellekaan NG, Young GP and James RJ: Reduced accumulation of
specific microRNAs in colorectal neoplasia. Mol Cancer Res.
1:882–891. 2003.PubMed/NCBI
|
|
35
|
Orang AV and Barzegari A: MicroRNAs in
colorectal cancer: From diagnosis to targeted therapy. Asian Pac J
Cancer Prev. 15:6989–6999. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Kijima T, Hazama S, Tsunedomi R, Tanaka H,
Takenouchi H, Kanekiyo S, Inoue Y, Nakashima M, Iida M, Sakamoto K,
et al: MicroRNA-6826 and −6875 in plasma are valuable non-invasive
biomarkers that predict the efficacy of vaccine treatment against
metastatic colorectal cancer. Oncol Rep. 37:23–30. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Wang J, Du Y, Liu X, Cho WC and Yang Y:
MicroRNAs as regulator of signaling networks in metastatic colon
cancer. Biomed Res Int. 2015:8236202015.PubMed/NCBI
|
|
38
|
Amirkhah R, Schmitz U, Linnebacher M,
Wolkenhauer O and Farazmand A: MicroRNA-mRNA interactions in
colorectal cancer and their role in tumor progression. Genes
Chromosomes Cancer. 54:129–141. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Ren L, Xiao L, Hu J, Li Z and Wang Z: MDR1
and MDR3 genes and drug resistance to cisplatin of ovarian cancer
cells. J Huazhong Univ Sci Technolog Med Sci. 27:721–724. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Stordal B, Hamon M, McEneaney V, Roche S,
Gillet JP, O'Leary JJ, Gottesman M and Clynes M: Resistance to
paclitaxel in a cisplatin-resistant ovarian cancer cell line is
mediated by P-glycoprotein. PLoS One. 7:e407172012. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Hayden MS and Ghosh S: Signaling to
NF-kappaB. Genes Dev. 18:2195–2224. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Sen R and Baltimore D: Multiple nuclear
factors interact with the immunoglobulin enhancer sequences. Cell.
46:705–716. 1986. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Sakamoto K and Maeda S: Targeting
NF-kappaB for colorectal cancer. Expert Opin Ther Targets.
14:593–601. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Sakamoto K, Maeda S, Hikiba Y, Nakagawa H,
Hayakawa Y, Shibata W, Yanai A, Ogura K and Omata M: Constitutive
NF-kappaB activation in colorectal carcinoma plays a key role in
angiogenesis, promoting tumor growth. Clin Cancer Res.
15:2248–2258. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Voboril R and Weberova-Voborilova J:
Constitutive NF-kappaB activity in colorectal cancer cells: Impact
on radiation-induced NF-kappaB activity, radiosensitivity, and
apoptosis. Neoplasma. 53:518–523. 2006.PubMed/NCBI
|
|
46
|
Lind DS, Hochwald SN, Malaty J, Rekkas S,
Hebig P, Mishra G, Moldawer LL, Copeland EM III and Mackay S:
Nuclear factor-κB is upregulated in colorectal cancer. Surgery.
130:363–369. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Wang S, Liu Z, Wang L and Zhang X:
NF-kappaB signaling pathway, inflammation and colorectal cancer.
Cell Mol Immunol. 6:327–334. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Vaiopoulos AG, Athanasoula KC and
Papavassiliou AG: NF-κB in colorectal cancer. J Mol Med (Berl).
91:1029–1037. 2013. View Article : Google Scholar : PubMed/NCBI
|
